Ocugen
About Ocugen
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Company Metrics
- Employees: 51-100
- Monthly Visits: 9972
- Tech Stack: 13 active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 190000000 USD
- Last Funding: 53500000 USD (Post-IPO Equity)
- Funding Status: IPO
Technology Stack
Ocugen actively uses 13 products in their tech stack.
Market Presence
Industries: Biopharma, Biotechnology, Health Care
Headquarters: Malvern, Pennsylvania, United States
Leadership
Employees
- Arun Upadhyay - CSO, Head of R&D & Manufacturing (LinkedIn)
- Robert Hopkins - Chief Medical Officer (LinkedIn)